Yet Another Value Podcast

Random Ramblings April 2025

7 snips
Apr 15, 2025
Andrew goes solo, sharing insights on the surprising corporate moves at KROS and the investor skepticism in the biotech sector. He critiques the industry's structural inefficiencies and emphasizes the need for stronger corporate governance. The conversation turns to the pitfalls of stock-based compensation in falling markets. He reflects on maintaining mental discipline in turbulent times and highlights the evolving role of AI in investment research, urging listeners to enhance their analytical toolkit.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Market Skepticism of KROS

  • KROS's strategic alternatives announcement led to a stock price increase, but the market remains skeptical.
  • This skepticism reflects investor mistrust in the biotech sector, as the stock still trades below cash value.
ADVICE

Engage with KROS Board

  • Contact KROS's board and express your opinion on the best path forward.
  • Shareholder engagement during the review period is crucial to ensure value creation.
INSIGHT

Biotech Nuclear Winter and Activism

  • Many pre-commercial biotech companies trade below cash value, indicating a nuclear winter in the sector.
  • Institutional investors hesitate to push for liquidation due to concerns about being labeled activists and losing future deal access.
Get the Snipd Podcast app to discover more snips from this episode
Get the app